Outlook Therapeutics与Mediconsult Ag达成瑞士独家分销协议 扩大欧洲版图

美股速递
Feb 19

Outlook Therapeutics, Inc.宣布与Mediconsult Ag签署独家商业分销协议,将旗下眼科药物Lytenava™(贝伐珠单抗γ)引入瑞士市场。这一战略合作标志着公司在欧洲业务布局的进一步扩展,有望提升其生物类似药产品在欧洲关键市场的可及性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10